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Abstract: Melanoma is the most aggressive and deadly form of skin cancer, which is largely due
to its propensity to metastasize. Therefore, with the aim to inhibit the growth and the metastatic
dissemination of melanoma cells and to provide a novel treatment option, we studied the effects of the
melanoma treatment with two organotin(IV) complexes of themeso-tetra(4-sulfonato-phenyl)porphine,
namely (Bu2Sn)2TPPS and (Bu3Sn)4TPPS. In particular, we showed that nanomolar concentrations
of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS are sufficient to inhibit melanoma cell growth, to increase the
expression of the full-length poly (ADP-ribose) polymerase (PARP-1), to induce the cell cycle arrest
respectively at G2/M and G0/G1 through the inhibition of the Cyclin D1 expression and to inhibit cell
colony formation. Nanomolar concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS are also sufficient
to inhibit the melanoma cell migration and the expression of some adhesion receptors. Moreover, we
report that (Bu2Sn)2TPPS and (Bu3Sn)4TPPS act downstream of BRAF, mainly bypassing its functions,
but targeting the STAT3 signalling protein. Finally, these results suggest that (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS may be effective therapeutic strategies for their role in the inhibition of melanoma
growth and migration.
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1. Introduction
Melanoma is the most aggressive form of skin cancer and unfortunately one of the most lethal
cancers worldwide, whose incidence rates are increasing rapidly in western populations [1,2]. Indeed,
the acquisition of invasive behaviour by metastatic melanoma cells is the key transition involved
in the decrease of melanoma patient survival rates. In particular, the metastatic transformation of
melanoma cells is a stepwise mechanism that depends on the increase of survival molecule mutations
that inhibit apoptotic pathways, allowing survival to hypoxia and oxidative stress [3] and increasing
the cellular migration and dissemination, which leads to the transformation of melanocytes into
metastatic melanoma. Indeed, despite the fact targeted therapies and immunotherapies have changed
significantly the metastatic melanoma treatment landscape [4], significant morbidity and mortality are
still associated with metastatic disease, and in fact only 32% of patients with metastatic melanoma have
a 5-year median survival rate, compared to almost 93% of patients with early melanoma lesions [5].
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Therefore, the melanoma field is in great need of studies to identify new efficient therapies suitable
for overcoming the intrinsic survival features acquired by melanoma cells to promote proliferation
and invasion. In this contest a group of organometallic compounds, the organotin complexes, widely
accepted in oncology as potential anticancer drugs, is very interesting [6,7]. The general formula
of organotin complexes is RnSnX(4−n), with n = 1 to 4, where the tin atom is covalently bound to
one or more organic alkyl or aryl groups (R) as well as to inorganic or organic ligands (X) [6]. The
nature and the number of the alkyl or aryl groups bound to the tin atoms of the organotin(IV) are
crucial for the anticancer activity of the complexes, while the ligands play a key role addressing
the organotin complexes to the target sites of the cells and modulating its cytotoxic activity [8–10].
Indeed, tin-based compounds can bind some membrane and cytoplasmic proteins such as receptors
and glycoproteins, can cross lipid bilayer membranes and reach the nucleus, where they can directly
interact with the DNA bases through intercalation, can also interact with the functional groups of the
DNA grooves and with the phosphate of the DNA phosphodiester backbones as anchoring sites for the
tin [11–13]. The consequences of these interactions are both the structural and functional alterations
of the membranes and the induction of DNA damage that leads to the blockage of cell division and
cell growth of organotin(IV)-treated cancer cells [6,8–10,14–16]. Moreover, the ligand molecules of the
organotin(IV) complexes, modifying the reactivity, the lipophilicity, the configuration and the molecular
structure of the complexes and therefore their binding activity and functions, play a significant role in
modulating the anti-tumour activity of the organotin(IV) moieties [12,17]. In particular, porphyrins
and porphyrin-based compounds are some interesting ligands for organotin(IV) moieties, due not only
to the property of the porphyrin to accumulate and to be retained by a variety of malignant lesions [18],
but also their function as drug delivery systems [19], bio-sensing and bio-imaging molecules [20].
Indeed, the organotin(IV) complexes have different mechanisms of action on different cancer cells and
induce tumour cell death in a concentration dependent manner [21,22]. In particular, organotin(IV)
complexes at higher concentrations, induce cancer cell death, but at lower concentrations organotin(IV)
complexes show antitumoral activity, inhibiting the cancer cell growth and therefore opening a new
field of study in the metal-pharmaceutical research area [21,22]. Therefore, with the aim to identify new
potential chemotherapeutic drugs that can inhibit the growth and metastatic dissemination of human
melanoma cells, we studied the effects of melanoma treatment with two organotin(IV) compounds,
namely the dibutyltin(IV) and tributyltin(IV) derivatives of meso-tetra(4-sulfonatophenyl)porphine,
(Bu2Sn)2TPPS and (Bu3Sn)4TPPS. The complexes were synthesized as previously reported [8] and were
isolated in the solid state as octahedral and trigonal-bipyramidal eq-R3Sn polymeric configurations,
respectively, for (Bu2Sn)2TPPS and (Bu3Sn)4TPPS complexes, with the arylsulfonate groups behaving
as monoanionic bidentate bridging ligands (Figure 1A,B).
We have previously reported the death due to apoptosis and in particular the activation of both
the intrinsic and the extrinsic apoptotic pathways in human melanoma cells treated with micromolar
concentrations of the (Bu2Sn)2TPPS and the (Bu3Sn)4TPPS [14,23–25]. In this paper we improved upon
and expanded this field of research by identifying that nanomolar concentrations of (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS that are sufficient to significantly induce the cell cycle arrest of some melanoma cell lines
through the inhibition of cyclin D1 expression.
We also reported that in melanoma cells (Bu2Sn)2TPPS and (Bu3Sn)4TPPS mediate inhibition of cell
colony formation as well as of the integrin and CAM adhesion receptors expression and therefore, the
inhibition of melanoma cell motility. Moreover, we showed that (Bu2Sn)2TPPS and (Bu3Sn)4TPPS act
downstream of BRAF, mainly bypassing its functions but probably targeting STAT3 signalling protein.
In conclusion, the compounds (Bu2Sn)2TPPS and (Bu3Sn)4TPPS, for their role in the regression of
the growth and migration of melanoma that we show in this paper, could deeply interfere with the
melanoma progression and metastatic dissemination as new strategies for an effective treatment of this
highly invasive tumour type.
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Figure 1. Polymeric octahedral configuration for (Bu2Sn)2TPPS (A) and polymeric trigonal-
bipyramidal configuration for (Bu3Sn)4TPPS (B), as characterized in the solid state [8]. 
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2. Materials and Methods
2.1. Cell Lines, Antibodies, Chemicals and Reagents
The A375 (ATCC-CRL-1619) [26], HT-144 (ATCC-HTB-63) and M74 melanoma cell lines (kindly
provided by Prof. C. Alcaide-Loridan, Institut Jacques Monod, Paris Diderot University, Paris, France)
harbouring the BRAF V600E mutation, were grown in RPMI 1640 supplemented with 10% FCS
and 1% penicillin-streptomycin (10,000 U/mL and 10,000 µg/mL, respectively) in 5% CO2 at 37 ◦C.
The A375 cell line was isolated from a primary tumour on the skin and can form metastatic foci in
nude mice [27]; the HT-144 cell line was isolated from a metastatic site on subcutaneous tissue [28]
and the M74 cell line was established from metastatic tumour fragments [29]. The organotin(IV)
meso-tetra(4-sulfonatophenyl)porphinate complexes, (Bu2Sn)2TPPS (formula weight FW = 1397)
and (Bu3Sn)4TPPS (formula weight FW = 2091), were synthesized as previously reported [8] by
refluxing, in dry methanol, Bu2SnO or (Bu3Sn)2O (gifts from Witco GmbH, Bergkamen, Germany), and
meso-tetra(4-sulfonatophenyl)porphine (=H4TPPS) of high purity, obtained from Porphyrin Products
(Logan, UT, USA). The (Bu2Sn)2TPPS and the (Bu3Sn)4TPPS were dissolved in dimethylsulfoxide
(DMSO) to obtain a 200 µM stock solution before each treatment. Furthermore, the stock solutions
were diluted in culture medium at various concentrations and before each treatment; in these solutions
the final DMSO concentration did not exceed 0.05% (v/v). As a control, equal volumes of DMSO
were added to untreated cells. The anti-pTyr-397 FAK motif, integrin β1, ICAM-1 and MCAM mouse
monoclonal antibodies were obtained from BD Biosciences (Lexington, KY, USA). The anti-integrin
β3, FAK and cyclin D1 rabbit polyclonal antibodies and the anti-BRAF mouse monoclonal antibody
were obtained from Santa Cruz (Santa Cruz, CA, USA). The anti-PARP-1 rabbit polyclonal antibody
was purchased from Cell Signaling Technology (Leiden, The Netherlands). The mouse monoclonal
antibody direct against β-actin was obtained from Sigma (St Louis, MO, USA). The anti-mouse and
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anti-rabbit Alexa Fluor 680 conjugated and the infrared dye-conjugated IRDye800 anti-mouse and
anti-rabbit were purchased as secondary antibodies from Molecular Probes (Eugene, OR, USA) and
LI-COR Biosciences (Lincoln, NE, USA), respectively. All other chemicals were of analytical grade and
were obtained from Sigma Chemical Co. (St Louis, MO, USA), Merck/VWR Readington, NJ, USA) or J.
T. Baker (Phillipsburg, NJ, USA).
2.2. Cell Viability Assay (MTS Assay)
A375 (0.5 × 104 per well) or HT-144 and M74 human melanoma cells (1 × 104 per well) were seeded
in 96-well plates for 24 h. Thereafter, the cells were treated with (Bu2Sn)2TPPS and (Bu3Sn)4TPPS or
with DMSO as reported, for 24 h, 48 h and 72 h in triplicate and the cell viability was determined
using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H–tetrazolium
(MTS) proliferation assay, following the instructions of the CellTiter-96 AQueous One Solution Cell
Proliferation Assay (Promega, Madison, WI, USA). The plates were scanned at 490 nm in a 96-well plate
reader after 30 min, 1 h, 1 h 30 min and 2 h. Cell viability for each treatment was normalized against
DMSO treated cells. The concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS required to achieve 50 %
inhibition of the A375, HT-144 and M74 cell viability compared to untreated cell viability (IC50 values),
were calculated after 24 h, 48 h and 72 h of treatment using a dose-response curve (Excel, Microsoft,
Redmond, WA, USA).
2.3. Total Cell Extracts and Western Blot Analysis
Semi-confluent A375, HT-144 and M74 human melanoma cells were treated with (Bu2Sn)2TPPS
and (Bu3Sn)4TPPS or with DMSO as reported, for 24 h, 48 h and 72 h. Therefore, the cells were
lysed as previously reported [30], in particular we used RIPA buffer (50 mM Tris-HCl pH 8, 150 mM
NaCl, 1% NP40, 0.5% DOC, 0.1% SDS) containing proteases and phosphatase inhibitors (4 mM PMSF
and protease inhibitors cocktail, cocktail 2 and 3 of phosphatase inhibitors, Sigma, St Louis, MO,
USA) for 30 min on ice. The cells in lysis buffer, were cleared of cellular debris by centrifugation at
12,000× g at 4 ◦C for 30 min. The Bradford protein assay (Bio-Rad laboratories GmbH, München,
Germany) was used to determine the protein concentration of the supernatants. Forty µg of total cell
extracts were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
absorbed to nitrocellulose membrane (Hybond ECL, GE Healthcare Biosciences, Pittsburgh, PA, USA).
After overnight incubation at 4 ◦C in blocking buffer (LI-COR Biosciences, Lincoln, NE, USA), the
nitrocellulose membrane was incubated at room temperature for 1 h 30 min with primary antibodies
and anti-mouse or anti-rabbit infrared fluorescent-labelled secondary antibodies (IRDye800, LI-COR
Biosciences, Lincoln, NE, USA and Alexa Fluor 680 conjugated, Molecular Probes, Eugene, OR, USA)
diluted in blocking solution (LI-COR Biosciences, Lincoln, NE, USA) and TBS-Tween buffer. The protein
bands were scanned and the band intensities of each western blot were quantified by densitometric
analysis, using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA). In the
histograms are reported the mean values of several western blot experiments of almost three different
experiments and are expressed as a per cent of unstimulated cells, normalized for the actin amount.
2.4. Cell Cycle Analysis
Semiconfluent A374, HT-144 and M74 melanoma cells treated for 72 h with (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS or with DMSO as reported, were washed twice with ice-cold PBS and resuspended at
1 × 106 cells/ml in hypotonic fluorochrome solution (0.1% sodium citrate, 0.03% Nonidet P-40 and
50 µg/ml propidium iodide) for 30 min at room temperature in the dark. Therefore, the cells were
acquired on a FACSCalibur™ flow cytometer, supported by CellQuest acquisition and data analysis
software (Becton Dickinson, Mountain View, CA, USA).
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2.5. Cell Colony Assay
A374, HT-144 and M74 melanoma cells (1.8 × 102, 10.8 × 102 and 18 × 102 cells, respectively)
were seeded in a 12-well cell culture plate and treated for 72 h with (Bu2Sn)2TPPS and (Bu3Sn)4TPPS
or with DMSO as reported. Afterwards, the treated and untreated cells were maintained in fresh
medium for 7–14 days, were fixed in 100% methanol and stained with 0.5% crystal violet in 20%
methanol. Therefore, the plates were air dried, the colonies were photographed using a digital camera
and counted.
2.6. Cell Migration Assay
The A375 and HT-144 melanoma cells were treated as reported with (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS or with DMSO for 72 h. After treatment, as previously reported [30], 1.6 × 104 of
A375 and HT-144 melanoma cells were plated in serum-free medium in the inner chamber of a 24-well
culture plate (Falcon, Bredford, MA, USA) with a polyethylene terephthalate (PET) membrane (pore
size, 8 µm; Falcon, Bredford, MA, USA) [31]. The lower wells were filled with RPMI supplemented
with 10% FBS. After 16 h at 37 ◦C the cells in the upper chamber were removed with a cotton swab and
the migrated cells attached to the lower surface of the transwell membrane were fixed for 20 min with
100% methanol and stained for 1h with 0.5% crystal violet in 20% methanol. After staining, all the
cells on the lower side of the filters were counted under phase contrast microscope (Leica, Wetzlar,
Germany).
3. Results
3.1. Inhibition of Melanoma Cell Proliferation
With the aim of identifying the minimum concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS
(Figure 1A,B) sufficient to inhibit the growth of the A375, HT-144 and M74 human melanoma cell lines,
we analysed the cellular growth of melanoma cells treated with (Bu2Sn)2TPPS concentrations ranging
from 100 nM to 600 nM and with (Bu3Sn)4TPPS ranging from 60 nM to 120 nM, for 24 h, 48 h and 72 h,
through MTS assays (Figure 2). The results of these experiments showed that the treatment of A375
and HT-144 cells with 200 nM and of M74 cells with 300 nM of (Bu2Sn)2TPPS and the treatment of
A375, HT-144 and M74 cells with 80 nM, 60 nM and 100 nM of (Bu3Sn)4TPPS, respectively, induce
the inhibition (Figure 2A, right panel, Figure 2B left panel and Figure 2C, left and right panels) or the
decrease (Figure 2A, left panel and Figure 2B, right panel) of the cell proliferation to a greater extent
after 48–72 h of treatment, compared to untreated cells (NT). Interestingly, the IC50 values obtained
for both compounds are higher than the amounts required to inhibit or reduce the cell proliferation
(Figure 2). The A375, the HT-144 and the M74 human melanoma cell lines express the mutated form
V600E of BRAF, in the A375 and in the M74 cells the promoter of the telomerase reverse transcriptase
(TERT) is mutated and in M74 cells the expression of p53 is very low, furthermore in the HT-144
cells also the Ataxia Telangiectasia Mutated (ATM) protein is mutated [32–34]. All these mutations
could induce a different growth rate of melanoma cells and also different sensitivity to the treatment
with (Bu2Sn)2TPPS and with (Bu3Sn)4TPPS compounds. In particular, ATM is activated by DNA
double-strand breaks (DSB), is involved in cell-cycle control, DSB repair and in the block of the cell
cycle progression [35]. Therefore, the mutation of ATM in HT-144 cells could slow down the response
to the (Bu3Sn)4TPPS compound used in these experiments that probably, for its high DNA binding
affinity, induces DNA damage in melanoma cells. Furthermore, in A375 and M74 melanoma cells, the
mutation of TERT promoter, could be associated with increased TERT expression and cell survival [32].
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Figure 2. MTS assay of A375, HT-144 and M74 melanoma cells treated with (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS. The (A) A375 cells were tre ted with 100 nM, 200 nM and 400 nM of (Bu2Sn)2TPPS (left),
or with 60 nM, 80 nM and 120 nM of (Bu3Sn)4TPPS (right); (B) the HT-144 cells were treated with 100
nM, 200 nM and 400 nM of (Bu2Sn)2TPPS (left), or with 60 nM, 80 nM and 100 nM of (Bu3Sn)4TPPS
(right); (C) the M74 cells were treated with 300 nM, 500 nM and 600 n of (Bu2Sn)2TPPS (left), or with
80 nM, 100 nM and 120 nM of (Bu3Sn)4TPPS (right) for 24 h, 48 h and 72 h and the cell proliferation
rate of untreated (NT) and treated melanoma cells, was analysed through MTS assay. In the histograms
(A–C) are reported the mean values of almost three different experiments performed in triplicate. The
error bars indicate the standard deviation, statistical significance was analysed by the Student’s t-test:
*p < 0.05 was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant.
The IC50 values are also reported using the values of three different experiments performed in triplicate.
Furthermore, in the light of the results of the MTS assay, we treated the A375, HT-144 and
M74 melanoma cells for 24 h, 48 h and 72 h with 250 nM, 200 nM and 300 nM, respectively, of
(Bu2Sn)2TPPS and with 80 nM, 60 nM and 100 nM of (Bu3Sn)4TPPS, to study the consequences of the
melanoma treatment with low concentrations of the complexes. Indeed, in the following experiments
we treated the A375 cells with 250 nM of (Bu2Sn)2TPPS instead of the 200 nM used in MTS assay
sufficient only to decrease the A375 proliferation rate. In particular, we analysed through western
blot experiments, the expression of the poly (ADP-ribose) polymerase (PARP-1) (Figure 3), using an
antibody direct against the full-length and the cleaved forms of PARP-1. Indeed, PARP-1 is a nuclear
enzyme that plays a pivotal role in many processes such as the repair of DNA single and double
strand breaks [36,37] and its cleavage is an apoptotic marker and an indicator of caspase activation [38].
Therefore, we showed that the treatment with (Bu2Sn)2TPPS (Figure 3A–C, left and right panels)
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and with (Bu3Sn)4TPPS (Figure 3A–C, middle and right panels), led to a significant increase of the
full-length form of PARP-1 that is more evident in A375 and HT-144 melanoma cells treated with
(Bu3Sn)4TPPS (Figure 3A,B, middle and right panels), but do not induce the cleavage of PARP-1 in
treated melanoma cells (Figure 3A–C). Therefore, the increase of full-length form of PARP-1 but the
lack of PARP-1 cleavage, strongly suggest that these treatments induce DNA damage but do not induce
the death for apoptosis of treated melanoma cells.
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Figure 3. Kinetics of PARP-1 expression in A375, HT-144 and M74 melanoma cells treated with
(Bu2Sn)2TPPS and (Bu3Sn)4TPPS. The kinetics of PARP-1 expression was analysed through western
blot experiments in (A) A375, (B) HT-144 and (C) M74 cell lines in response to the treatment with 250
nM, 200 nM and 300 nM of (Bu2Sn)2TPPS (left and right panels) and with 80 nM, 60 nM and 100 nM of
(Bu3Sn)4TPPS respectively (middle and right panels) for 24 h, 48 h and 72 h. The analysis of the β-actin
expression (A, B and C, lower panels) was used to confirm the equal protein loading. The error bars
indicate the standard deviation. The Student’s t-test was used to the analysis of statistical significance:
*p < 0.05 was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant (A,
B and C, right panels).
Furthermore, we analysed through western blot experiments, the expression of BRAF (Figure 4), a
key signalling protein which plays a critical role in the regulation of cellular growth and proliferation [39].
In particular, we showed the increased expression of BRAF in treated cells compared to untreate
cells (NT), that is more evident in melanoma cells treated with (Bu3Sn)4TPPS (Figure 4A–C, middle
and right panels). Therefore, the in ibition of the cellular proliferation but the increase of the BRAF
expression, strongly suggest that these treatments can bypass some of the BRAF functions.
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Figure 4. Kinetics of BRAF expression in A375, HT-144 and M74 melanoma cells treated with
(Bu2Sn)2TPPS and (Bu3Sn)4TPPS. The kinetics of BRAF expression was alysed in (A) A375, (B)
HT-144 and (C) M74 cell lines treated w th 250 nM, 200 nM and 300 nM of (Bu2Sn)2TPPS (left and right
panels) and with 80 nM, 60 nM and 100 nM of (Bu3S )4TPPS (middle and right panels) respectively,
for 24 h, 48 h and 72 h through western blot experiments. The analysis of the β-actin expression (A,
B and C, lower panels) was used to confirm th equal prot in load ng. The error bars indicate the
standard deviation. The Stud nt’s t-test was used to the analysis of statistical significance: *p < 0.05
w s consi red significant; **p < 0.01 highly significant; ***p < 0.001 very high y significant (A, B and
C, right panels).
3.2. Cell Cycle Arrest of Treated Melanoma Cells
The highly conserved DNA-repair and cell cycle checkpoint pathways, are some mechanisms
activated by the cells in response to DNA damage, to delay the cell cycle progression, to identify errors
and to efficiently repair the damaged DNA [40]. Therefore, with the aim to further investigate the
mechanisms used by these compounds to inhibit the cellular growth, we treated the A375, HT-144 and
M74 cells with respectively 250 nM, 200 nM and 300 nM of (Bu2Sn)2TPPS and with 80 nM, 60 nM and
100 nM of (Bu3Sn)4TPPS for 72 h and the cell cycle distribution of treated and untreated melanoma
cells was analysed by flow cytometry (Figure 5). In particular, we showed that the (Bu2Sn)2TPPS
treatment decreases the rate of A375, HT-144 and M74 melanoma cells in G0/G1 phase (38.50%, 37.43%
and 67.39%) compared to untreated cells (NT) (65.69%, 63.07% and 74.26%), but increases the rate
of the cells in G2/M phase (34.98%, 32.61% and 29.72%) compared to untreated cells (NT) (20.46%,
18.44% and 16.81%) (Figure 5A,C,E). Otherwise, the (Bu3Sn)4TPPS treatment increases the rate of A375,
HT-144 and M74 melanoma cells in G0/G1 phase (68.88%, 65.96% and 86.49%) compared to untreated
cells (NT) (63.68%, 61.44% and 73.41%), but decreases the rate of the cells in G2/M phase (18.11%,
16.52% and 7.01%) compared to untreated cells (NT) (23.02%, 20.39% and 14.81%), (Figure 5B,D,F).
Therefore, the results of these experiments show that (Bu2Sn)2TPPS and the (Bu3Sn)4TPPS exert their
anti-proliferative effects in melanoma cells through the blockage of cell cycle progression using different
mechanisms (Figure 5).
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as mean values of almost three different experiments, the error bars indicate the standard deviation 
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untrea ed (NT) or t eated for 72 h, (A,B), HT-144 (C,D) and M74 (E,F) melano a cells with
(A) 250 nM, (C) 200 , (E) 300 nM of (Bu2Sn)2TPP and with (B) 80 nM, (D) 60 nM, (F) 100 nM of
(Bu3Sn)4TPPS respectively, were stained with PI. The fluorescence of PI-stained cells was analysed
through flow cytometry to identify the percentage rate of cells in G0/G1, S and G2/M phases of the
cell cycle. In the histograms (A–F, lower panels) the cell fractions of treated cells in G0/G1, S and
G2/M phase of the cell cycle are expressed as a per cent of the cell fractions of untreated cells and
as mean values of almost three different experiments, the error bars indicate the standard deviation
and statistical significance was analysed by the Student’s t-test: *p < 0.05 was considered significant;
**p < 0.01 highly significant; ***p < 0.001 very highly significant.
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Interestingly, each stage of the cell cycle is regulated by different complexes of the cyclin dependent
kinases (CDKs) and of their regulatory partners, the cyclins [41]. Therefore, the expression of cyclin
D1, a key regulator mainly of the G1/S [42] but also of the G2/M phases, was analysed by western
blot experiments (Figure 6) on A375, HT-144 and M74 melanoma cells treated as reported for 24 h,
48 h and 72 h with (Bu2Sn)2TPPS and with (Bu3Sn)4TPPS. We showed that, as expected, a larger
decrease of the cyclin D1 expression in (Bu3Sn)4TPPS-treated melanoma cells blocked in the G0/G1
phase (Figure 6A–C, middle and right panels) compared to the cells treated with (Bu2Sn)2TPPS and
blocked in G2/M phase (Figure 6A–C, left and right panels). Interestingly, these results suggest that
the treatment with nanomolar concentration of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS induce G2/M and
the G0/G1 cell cycle arrest, respectively, through the inhibition of cyclin D1 expression, although with
different quantitative effects (Figure 6).
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3.3. Cell Colony Formation  
The hallmark of chemotherapeutic drugs is the inhibition of cellular proliferation as well as the 
reduction of cell viability. Therefore, the ability of the A375, HT-144 and M74 cell lines to form 
colonies after treatment for 72 h with (Bu2Sn)2TPPS (250 nM, 200 nM and 300 nM, respectively) and 
with (Bu3Sn)4TPPS (80 nM, 60 nM and 100 nM, respectively) was analysed (Figure 7). Interestingly, 
the (Bu2Sn)2TPPS and the (Bu3Sn)4TPPS treatments highly inhibited the ability of melanoma cells to 
Figure 6. Kinetics of cyclin D1 expression in A375, HT-144 and M74 melanoma cells treated with
(Bu2Sn)2TPPS and (Bu3Sn)4TPPS. The kinetics of cyclin D1 (CD1) expression was analysed in (A) A375,
(B) HT-144 and (C) M74 cell lines treated with 250 nM, 200 nM and 300 nM of (Bu2Sn)2TPPS (left
and right panels) and with 80 nM, 60 nM and 100 nM of (Bu3Sn)4TPPS (middle and right panels)
respectively, for 24 h, 48 h and 72 h, through western blot experiments. The analysis of the β-actin
expression (A, B and C, lower panels) was used to confirm the equal protein loading. The error bars
indicate the standard deviation. The Student’s t-test was used to the analysis of statistical significance:
*p < 0.05 was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant (A,
B and C, right panels).
3.3. Cell Colony Formation
The hallmark of chemotherapeutic drugs is the inhibition of cellular proliferation as well as the
reduction of cell viability. Ther fore, the ability of t e A375, HT-144 and M74 cell lines to form colonies
after reatment for 72 h with (Bu2Sn)2TPPS (250 nM, 200 nM and 300 nM, respectively) and with
(Bu3Sn)4TPPS (80 nM, 60 nM and 100 nM, respectively) was analysed (Figure 7). Interestingly, the
(Bu2Sn)2TPPS and the (Bu3Sn)4TPPS treatments highly inhibited the ability of melanoma cells to form
colonies, in particular the A375, HT-144 and M74 cell lines treated with (Bu2Sn)2TPPS, displayed 11.44%,
14.52% and 9.60%, respectively, while the A375, HT-144 and M74 cell lines treated with (Bu3Sn)4TPPS,
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displayed 2.63%, 6.71% and 1.62%, respectively, of cell colony formation activity compared to untreated
cells (Figure 7A–C). Therefore, our results showed that the treatment with nanomolar concentrations
of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS reduces the cell viability and the survival rate of melanoma cells.
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3.4. Expression of Adhesion Receptors and FAK Signalling Protein  
The adhesion receptors are important actors in melanoma metastatic dissemination defining the 
cellular shape and regulating cell mobility and invasiveness [3,43]. Therefore, to better understand 
the mechanisms used by (Bu2Sn)2TPPS and (Bu3Sn)4TPPS to inhibit the metastatic dissemination of 
melanoma cells, we analysed the expression of integrin β1 and β3 (Figures 8 and 9), MCAM and 
ICAM (Figure 10) adhesion receptors in A375 (Figures 8, 10A and 10C) and HT-144 (Figures 9, 10B 
Figure 7. Cell colony assay of 375, T-144 and 74 elano a cells treated ith nano olar
concentration of (Bu Sn)2TPPS and (Bu3Sn)4TPPS. The A375 (A), the HT-144 (B) and the 74 (C)
elano a cells were treated for 72h with 250, 200 and 300 n of (Bu Sn) TPPS (left) and with 80, 60
and 100 n of (Bu Sn) TPPS (right), respectively. After 7–14 days of growth in fresh medium, the
colonies of treated and untreated cells were fixed, stained, photographed using a digital camera and
counted. The colony formation efficiency of treated cells is the number of the colonies formed by
treated cells expressed as a per cent of colonies formed by untreated cells (NT). These data are reported
in the histograms (A–C, left panels) as the mean values of almost three different experiments performed
in triplicate. The error bars indicate the standard deviation and statistical significance was analysed by
the Student’s t-test: ***p < 0.001 very highly significant.
3.4. Expression of Adhesion Receptors and FAK Signalling Protein
The adhesion receptors are important actors in melanoma metastatic dissemination defining the
cellular shape and regulating cell mobility and invasiveness [3,43]. Therefore, to better understand
the mechanisms used by (Bu2Sn)2TPPS and (Bu3Sn)4TPPS to inhibit the metastatic dissemination of
melanoma cells, we analysed the expression of integrin β1 and β3 (Figures 8 and 9), MCAM and ICAM
(Figure 10) adhesion receptors in A375 (Figure 8, Figure 10A,C) and HT-144 (Figure 9, Figure 10B,D)
cell lines treated for 24 h, 48 h and 72 h with 250 and 200 nM of (Bu2Sn)2TPPS, respectively, and with
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80 and 60 nM of (Bu3Sn)4TPPS, respectively. In particular we showed in A375 and HT-144 melanoma
cells treated with (Bu2Sn)2TPPS, the decreased expression of integrin β1 (Figures 8A and 9A, left and
right panels), integrin β3 (Figures 8B and 9B, left and right panels), MCAM (Figure 10A,B, left and
right panels) and ICAM (Figure 10C,D, left and right panels) adhesion receptors, with the exception of
the steady state level expression of integrin β3 after 72 h of treatment in both cell lines (Figures 8B and
9B, left and right panels), compared to untreated cells (NT).
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The (Bu3Sn)4TPPS treatment induces the decreased expression of integrin β1 in both cell lines 
(Figures 8A and 9A, middle and right panels), while the expression of integrin β3 decreased in A375 
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Figure 8. Kinetics of the integrins and FAK expression in A375 cells treated with (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS. The kinetics of (A) integrin β1, (B) integrin β3 adhesion receptors and of (C) FAK and
pFAK expression was analysed in A375 melanoma cells treated with 250 nM of (Bu2Sn)2TPPS (A, B
and C, left and right panels) and with 80 nM of (Bu3Sn)4TPPS (A, B and C, middle and right panels)
for 24 h, 48 h and 72 h, through western blot experiments. The analysis of the β-actin expression (A,
B and C, lower panels) was used to confirm the equal protein loading. The error bars indicate the
standard deviation. The Student’s t-test was used to the analysis of statistical significance: *p < 0.05
was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant (A, B and
C, right panels).
The (Bu3Sn)4TPPS treatment induces the decreased expression of integrin β1 in both cell lines
(Figures 8A and 9A, middle and right panels), while the expression of integrin β3 decreased in A375
cells (Figure 8B, middle and right panels) but increased in HT-144 cells (Figure 9B, middle and right
panels), compared to untreated cells (NT).
Finally, the (Bu3Sn)4TPPS treatment induces in both cell lines the increased expression of MCAM
(Figure 10A,B, middle and right panels) as well as the decreased expression of ICAM (Figure 10C,D,
middle and right panels) with the exception of the steady state level expression of ICAM after 72 h of
treatment in HT-144 cells (Figure 10D, middle and right panels).
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decrease in HT-144 cells treated with (Bu3Sn)4TPPS for 48 h and 72 h, (Figure 9C, middle and right 
panels). In conclusion, these results collectively showed that the treatment with nanomolar 
concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS induces in melanoma cells, although with different 
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cells treated with (Bu3Sn)4TPPS, the decreased expression and activation of FAK, thus suggesting that 
these complexes could inhibit the migration and metastatic dissemination of melanoma cells using 
different mechanisms. 
Figure 9. Kinetics of the integrins and FAK expression in HT-144 cells treated with (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS. The kinetics of (A) integrin β1, (B) integrin β3 adhesion receptors and of (C) FAK and
pFAK expression was analysed in HT-144 melanoma cells treated with 200 nM of (Bu2Sn)2TPPS (A, B
and C, left and right panels) and with 60 nM of (Bu3Sn)4TPPS (A, B and C, middle and right panels)
for 24 h, 48 h and 72 h, through western blot experiments. The analysis of the β-actin expression (A,
B and C, lower panels) was used to confirm the equal protein loading. The error bars indicate the
standard deviation. The Student’s t-test was used to the analysis of statistical significance: *p < 0.05
was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant (A, B and
C, right panels).
Integrin signalling leads to the activation of FAK through the auto-phosphorylation of the
Tyr-397 [44], therefore, we analysed in treated and untreated (NT) melanoma cells, the expression and
the activation of FAK signalling protein (Figures 8C and 9C) and we showed in (Bu2Sn)2TPPS-treated
cells that the expression and the activation of FAK are almost at the steady state level in both cell
lines (Figures 8C and 9C, left and right panels). Furthermore, we showed that the FAK expression
and activation increase in (Bu3Sn)4TPPS treated A375 cells, (Figure 8C, middle and right panels),
but decrease in HT-144 cells treated with (Bu3Sn)4TPPS for 48 h and 72 h, (Figure 9C, middle and
right panels). In conclusion, these results collectively showed that the treatment with nanomolar
concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS induces in melanoma cells, although with different
quantitative effects, the decreased expression of integrin and CAM adhesion receptors and in HT-144
cells treated with (Bu3Sn)4TPPS, the decreased expression and activation of FAK, thus suggesting that
these complexes could inhibit the migration and metastatic dissemination of melanoma cells using
different mechanisms.
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3.5. Analysis of Melanoma Cell Migration 
Indeed, a complex network of adhesion receptors and signalling molecules are involved in the 
multistep process required to manage the cell migration, that play a key role on the aggressive 
metastatic trend of melanoma [43]. Therefore, in A375 and HT-144 cell lines treated for 72 h with 250 
nM and 200 nM of (Bu2Sn)2TPPS, respectively, and with 80 nM and 60 nM of (Bu3Sn)4TPPS, 
respectively, we analysed the cellular migration ability (Figure 11). In particular, through the 
migration assay, we showed that the treatment for 72 h with (Bu2Sn)2TPPS and with (Bu3Sn)4TPPS 
decreases the migration ability of A375 cells (by 50.27% and 57.27%, respectively) (Figures 11A and 
11B) and of HT-144 cells (by 32.8% and 38.2%, respectively) (Figures 11C and 11D), compared to 
Figure 10. Kinetics of the CAMs expression in A375 and HT-144 cells treated with (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS. The kinetics of MCAM (A,B) and ICAM (C,D) expression was analysed in (A,C) A375
and in (B,D) HT-144 cell lines in response to the treatment with 250 nM and 200 nM of (Bu2Sn)2TPPS (left
and right panels) and with 80 nM and 60 nM of (Bu3Sn)4TPPS (middle and right panels) respectively,
for 24 h, 48 h and 72 h, through western blot experiments. The analysis of the β-actin expression (A,
B, C and D, lower panels) was used to confirm the equal protein loading. The error bars indicate the
standard deviation. The Student’s t-test was used to the analysis of statistical significance: *p < 0.05
was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant (A, B, C
and D, right panels).
3.5. Analysis of Melanoma Cell Migration
Indeed, a complex network of adhesion receptors and signalling molecules are involved in
the multistep process required to manage the cell migration, that play a key role on the aggressive
etastatic trend of melanoma [43]. Therefore, in A375 and HT-144 cell lines treated for 72 h with
250 nM and 200 nM of (Bu2Sn)2TPPS, respectively, and with 80 nM a d 60 nM of (Bu3Sn)4TPPS,
respectively, we analysed the cellular migration ability (Figure 11). In particular, through the migration
assay, we showed that the treatment for 72 h with (Bu2Sn)2TPPS and with (Bu3Sn)4TPPS decreases the
igration ability of A375 cells (by 50.27% and 57.27%, respectively) (Figure 11A,B) and of HT-144 cells
(by 32.8% and 38.2%, respectively) (Figure 11C,D), compared to untreated cells (NT). In conclusion, our
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results show that (Bu2Sn)2TPPS and (Bu3Sn)4TPPS treatment inhibit the migration and the spreading of
melanoma cells, thus suggesting that could play a main role on the treatment of metastatic melanoma.
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Figure 11. The treatment with nano l centrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS inhibit
the migration of A375 and HT-144 melanoma cells. The (A,B) A375 and (C,D) HT-144 melanoma cells
untr ated (NT) or treated for 72 h with (A) 250 nM, (C) 200 nM of (Bu2Sn)2TPPS and with (B) 80 nM,
(D) 60 nM of (Bu3Sn)4TPPS respectively, were lated in the inner chamber of a 24-well culture plate
with PET membrane (8 µm pore size) and incubated at 37 ◦C for 16 h. The migrated cells fixed and
stained, were counted under phase contrast microscope (Leica). The number of treated migrating cells,
are expressed as a per cent of the untreated migrating cells and reported in the histograms (A–D, left
panels) as the mean values of almost three different experiments performed in triplicate. The error bars
indicate the standard deviation and statistical significance was analysed by the Student’s t-test: *p <
0.05 was considered significant; **p < 0.01 highly significant; ***p < 0.001 very highly significant.
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3.6. Expression of STAT3 Signalling Protein
The STAT3 protein is often constitutively activated in melanoma cells and its inhibition in
melanoma induces cell death, tumour regression and the inhibition of metastatic dissemination [45,46].
Therefore, in A375 (Figure 12A) and in HT-144 (Figure 12B) cell lines treated for 24 h, 48 h and 72 h
with (Bu2Sn)2TPPS (250 nM and 200 nM, respectively) and with (Bu3Sn)4TPPS (80 nM and 60 nM,
respectively), we analysed through western blot the expression of STAT3 signalling protein (Figure 12).
In particular, we showed in both cell lines treated with (Bu2Sn)2TPPS (Figure 12A,B, upper and lower
panels) and with (Bu3Sn)4TPPS (Figure 12A,B, middle and lower panels), the decreased expression of
STAT3 compared to untreated cells (NT). In conclusion, these results indicate that in melanoma cells,
the STAT3 signalling protein is a target of the (Bu2Sn)2TPPS and (Bu3Sn)4TPPS that could mediate the
inhibition of melanoma proliferation and metastatic dissemination weakened by these complexes.
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Figure 12. Kinetics of STAT3 expression in A375 and HT-144 melanoma cells treated with (Bu2Sn)2TPPS
and (Bu3Sn)4TPPS. The kinetics of STAT3 expression was analysed in (A) A375 and (B) HT-144 cell lines
in response to the treatment with 250 nM and 200 nM of (Bu2Sn)2TPPS (A and B, higher and lower
panels) and with 80 nM and 60 nM of (Bu3Sn)4TPPS (A and B, middle and lower panels) respectively,
for 24 h, 48 h and 72 h, through western blot experiments. The analysis of the β-actin expression (A,B)
was used to confirm the equal protein loading. The error bars indicate the standard deviation. The
Student’s t-test was used to the analysis of statistical significance: *p < 0.05 was considered significant;
**p < 0.01 highly significant; ***p < 0.001 very highly significant (A and B, lower panels).
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4. Discussion
Melanoma is one of the most treatment-refractory malignancies, notorious for its propensity
to metastasize. Indeed, notwithstanding the effectiveness of new therapeutic approaches such
as immunotherapies and targeted therapies [4], the melanoma field is in great need to identify
new therapeutic approaches. Therefore, to improve the research of potential anticancer drugs, we
studied the effects of the treatment with nanomolar concentrations of two organotin(IV) complexes of
meso-tetra(4-sulfonatophenyl)porphine, (Bu2Sn)2TPPS and (Bu3Sn)4TPPS, on the growth and on the
metastatic dissemination of some human melanoma cell lines. In particular, we showed the induction of
a dose-dependent inhibition of cellular growth and respectively the G2/M and the G0/G1 cell cycle arrest,
the increased expression of the full-length PARP-1 as well as the inhibition of the cell colony formation
and cell migration. PARP-1(ADP-ribosyltransferase-1), a member of the poly-ADP-ribose polymerase
family, is involved in many different processes such as DNA single and double strand break repair [47],
chromatin modification, transcriptional regulation and cell death [36]. The activation of PARP-1 follows
his binding to the DNA strand breaks and enables PARP-1 to synthetize poly(ADP-ribose) (PAR) and
also to increase its own expression [47]. Therefore, the hypothesis that the melanoma cells treatment
with nanomolar concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS induces DNA damage, elicits the
increased expression of PARP-1 that, however, is not sufficient to repair an overwhelming amount
of DNA damage and to avoid the consequent block of cell cycle. However, in treated M74 cells we
reported a lower increase of PARP-1 expression compared to the expression level of PARP-1 in A375
and HT-144 treated cells, probably due to the low expression in M74 cells, of a PARP-1-activating
protein such as the p53 protein [34,48]. Furthermore, the A375, HT-144 and M74 human melanoma
cell lines harbouring the mutation V600E of BRAF, also express the mutated form of several common
and different proteins such as ATM in HT-144 cells, instead, in A375 and M74 cells the promoter
of TERT is mutated [32–34], thus eliciting the reported different sensitivity to the treatment with
(Bu2Sn)2TPPS and (Bu3Sn)4TPPS. Indeed, the hydrophobic butyl components of the (Bu2Sn)2TPPS
and the (Bu3Sn)4TPPS, can directly interact with DNA and in particular, the tin of the organotin(IV)
compounds can bind not only to the DNA bases but also the functional groups of the DNA grooves and
the phosphate of the DNA phosphodiester backbones [11–13,15]. Therefore, the high DNA binding
affinity of these organotin(IV) compounds and mostly of (Bu3Sn)4TPPS, elicits the alteration of the
DNA conformation [15] and the induction of DNA damage suggested by the increased expression
of the full-length PARP-1 as well as by the inhibition of the growth and by the blockage of the cell
cycle that we showed in treated melanoma cells. In particular, our hypothesis is that (Bu3Sn)4TPPS
has a higher DNA backbone affinity compared to (Bu2Sn)2TPPS and therefore the higher alteration
of the DNA conformation could explain the earlier stop of the cell cycle reported in (Bu3Sn)4TPPS
treated cells. Interestingly, we also showed in treated melanoma cells the decreased expression of the
protein cyclin D1, a key regulator of the G1/S but also of the G2/M phase transition [42]. Moreover,
cyclin D1 can promote cancer formation and cancer survival through the regulation of transcription,
DNA damage and repair, the induction of chromosomal instability as well as the enhancement of
angiogenesis, cell migration and invasion [49,50]. Therefore, in the light of the polyhedral functions
of cyclin D1, the inhibition of cancer growth and metastatic diffusion induced by these compounds
in melanoma cells, could be also mediated by the inhibition of cyclin D1 expression. Furthermore,
the treatment of melanoma cells carrying the BRAF mutation V600E with nanomolar concentrations
of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS induces the increased expression of BRAF, notwithstanding the
fact these treatments also induce the inhibition of cellular growth, the blockage of the cell cycle, the
inhibition of cell colony formation and the inhibition of the expression of a BRAF target such as cyclin
D1 [51]. BRAF is a serine-threonine protein kinase mutated in almost the 50%–60% of melanomas [2]
mostly harbouring the mutation V600E that increases the protein kinase activity, the consequent
activation of the BRAF/MAPK/ERK signalling pathways and therefore the tumour cell growth and
proliferation [39]. Therefore, the reported results show that the downstream functions of BRAF, such as
melanoma growth, mobility and invasiveness are irreparably compromised, suggest that (Bu2Sn)2TPPS
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and (Bu3Sn)4TPPS act downstream of BRAF mainly bypassing its functions. Indeed, these results
make it appealing to follow up the studies of the signalling pathways inhibited by (Bu2Sn)2TPPS
and (Bu3Sn)4TPPS treatment as very interesting therapeutic strategies. Melanoma can metastasize
spreading beyond the primary tumour and this aggressive metastatic trend is mediated by some
adhesion receptors that promote the cell migration during each phase of cancer development and
progression but also promote the metastatic dissemination of cancer cells [3,43]. In melanoma cells the
treatment with nanomolar concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS is mostly associated,
although with different outcomes, to a significant decrease of the expression of integrin and CAM
adhesion receptors and especially to the consequent inhibition of the cellular motility. The lipophilicity
of the butyl moieties [15] enables (Bu2Sn)2TPPS and (Bu3Sn)4TPPS to cross and to intercalate the
lipid bilayer of the membrane, to bind phospholipids, glycoproteins and receptors, thus modifying
the structure and functionality of the membranes [52], could explain the reported results. Therefore,
the decreased expression of integrin and CAM adhesion receptors in treated melanoma cells, could
inhibit not only the cellular motility, but also the homologous and heterologous interactions between
melanoma and endothelial cells thus preventing the cells from assembling in clumps and the melanoma
intravasation, extravasation and metastatic spread. Finally, we showed the inhibition of the STAT3
expression, a key protein implicated in the regulation of growth, survival, invasion, migration and
metastatic spread of tumour cells [53]. Therefore, our hypothesis is that the STAT3 inhibition could
also mediate the inhibition of melanoma proliferation and metastatic dissemination that we showed in
treated melanoma cells.
The available chemotherapeutic drugs have a generally low effect on the growth of melanoma
cells but the results that we show suggest that nanomolar concentrations of (Bu2Sn)2TPPS and
(Bu3Sn)4TPPS could target multiple molecular pathways in melanoma cells. Therefore, (Bu2Sn)2TPPS
and (Bu3Sn)4TPPS, for their role in the regression of melanoma motility and metastatic dissemination,
could deeply interfere with the melanoma progression as new strategies for an effective treatment of
this highly invasive tumour.
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